Dynavax Technologies | DVAX - Gross Profit On Sales


Dynavax Technologies reported $78.57M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.



Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Adma Biologics USD 88.82M 13.19M Dec/2025
Agenus USD 34.2M 4.61M Dec/2025
Amgen USD 6.48B 307M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Gilead Sciences USD 6.31B 106M Dec/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Merck USD 13.42B 431M Sep/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Novartis USD 10.25B 570M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
TG Therapeutics USD 154.43M 20.81M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025